SG11202100677VA - Mature virus-like particles of flaviviruses - Google Patents

Mature virus-like particles of flaviviruses

Info

Publication number
SG11202100677VA
SG11202100677VA SG11202100677VA SG11202100677VA SG11202100677VA SG 11202100677V A SG11202100677V A SG 11202100677VA SG 11202100677V A SG11202100677V A SG 11202100677VA SG 11202100677V A SG11202100677V A SG 11202100677VA SG 11202100677V A SG11202100677V A SG 11202100677VA
Authority
SG
Singapore
Prior art keywords
flaviviruses
particles
mature virus
mature
virus
Prior art date
Application number
SG11202100677VA
Inventor
Nopporn Sittisombut
Malinee Sae-Lim
Nicha Charoensri
Poonsook Keelapang
Original Assignee
Chiang Mai Univ
National Science And Tech Development Agency Nstda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiang Mai Univ, National Science And Tech Development Agency Nstda filed Critical Chiang Mai Univ
Publication of SG11202100677VA publication Critical patent/SG11202100677VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24171—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202100677VA 2019-05-28 2019-05-28 Mature virus-like particles of flaviviruses SG11202100677VA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/TH2019/000015 WO2020242388A1 (en) 2019-05-28 2019-05-28 Mature virus-like particles of flaviviruses

Publications (1)

Publication Number Publication Date
SG11202100677VA true SG11202100677VA (en) 2021-02-25

Family

ID=66999891

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202100677VA SG11202100677VA (en) 2019-05-28 2019-05-28 Mature virus-like particles of flaviviruses

Country Status (8)

Country Link
US (1) US20210324013A1 (en)
EP (1) EP3976768A1 (en)
JP (1) JP7221995B2 (en)
KR (1) KR102646666B1 (en)
CN (1) CN112334576B (en)
AU (1) AU2019447736B2 (en)
SG (1) SG11202100677VA (en)
WO (1) WO2020242388A1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201591888A1 (en) * 2008-03-14 2016-05-31 Санофи Пастер Байолоджикс Ко. REPLICATION-DEFECT VACCINES AND VACCINE VECTORS AGAINST FLAVIVIRUSS
CA2658259A1 (en) * 2009-03-12 2010-09-12 Institut Pasteur Dengue virus-like particle and uses thereof
WO2013151764A1 (en) * 2012-04-02 2013-10-10 The University Of North Carolina At Chapel Hill Methods and compositions for dengue virus epitopes
CA2960102C (en) * 2014-09-11 2023-10-24 Vlp Therapeutics, Llc Flavivirus virus like particle
GB201610162D0 (en) * 2016-06-10 2016-07-27 Imp Innovations Ltd And Inst Pasteur Methods
US10898566B2 (en) * 2016-09-19 2021-01-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Zika virus vaccines

Also Published As

Publication number Publication date
JP7221995B2 (en) 2023-02-14
AU2019447736B2 (en) 2022-08-25
CN112334576B (en) 2023-06-02
WO2020242388A1 (en) 2020-12-03
AU2019447736A1 (en) 2021-02-11
KR20210027285A (en) 2021-03-10
US20210324013A1 (en) 2021-10-21
CN112334576A (en) 2021-02-05
JP2021528081A (en) 2021-10-21
EP3976768A1 (en) 2022-04-06
KR102646666B1 (en) 2024-03-11

Similar Documents

Publication Publication Date Title
HK1255670A1 (en) Modified virus-like particles of cmv
HK1246358A1 (en) Preparation of high purity collagen particles and used thereof
EP3389862C0 (en) Method of producing spheroidal dehydrogenated titanium alloy particles
IL247309A0 (en) Compositions for the inactivation of virus replication and methods of making and using the same
EP4004036A4 (en) Virus-like particle vaccines
HK1259274A1 (en) Human respiratory syncytial virus (hrsv) virus-like particles (vlps) based vaccine
EP3303571A4 (en) Live-attenuated virus and methods of production and use
IL269590A (en) Methods and compositions for reduction of immunogenicity
EP3484509A4 (en) Compositions and methods for flavivirus vaccination
EP3151786A4 (en) Compositions and methods for regeneration of hard tissues
SG11201700910QA (en) Suspension of a magnesium silicate, method for making same and use thereof as a phosphor
RS65084B1 (en) Canine parvovirus (cpv) virus-like particle (vlp) vaccines and uses thereof
EP3244994A4 (en) Compositions and methods for producing high purity filter aids
IL260022A (en) Preparation of respirable zafirlukast particles
GB201701573D0 (en) Virus-like particle
EP2964032A4 (en) Compositions and methods for the production of virus-like particles
PT3368673T (en) Compositions and methods for production of myrcene
EP3621660A4 (en) Compositions and methods of use of arc capsids
SG11202111111UA (en) Production of salipro particles
IL284135A (en) Virus-like particles of cmv modified by fusion
PT3233233T (en) Defoaming compositions comprising amphiphilic particles and methods of making and using the same
EP3236997A4 (en) Dengue virus vaccine compositions and methods of use thereof
EP3110435A4 (en) Methods and compositions for the delayed treatment of stroke
SG11202100677VA (en) Mature virus-like particles of flaviviruses
EP3420076C0 (en) Methods of producing and characterizing virus vaccine and virus vaccine composition